Submission guidelines for Chinese Journal of New Clinical Medicine

Chinese Journal of New Clinical Medicine was founded in 2008. It is a national medical academic scientific and technological journal (monthly) jointly sponsored by Chinese Medical Doctor Association and the People's Hospital of Guangxi Zhuang Autonomous Region, under the supervision of the responsible institution National Health Commission of the People's Republic of China. It is a core journal of China Science and Technology Paper and Citation Database (CSTPCD) and a core journal of  China Applied Core Journal ‌（CACJ）. International Standard Serial Number is ISSN 1674-3806, and its China National Standard Serial Number of the journal‌ is CN 45-1365/R, and its domestic postal distribution code is 48-173. It is publicly distributed both at home and abroad. Submission and subscribing to the journal are appreciated.

The mission of the journal is to report new achievements in medical science both at home and abroad, disseminate new theories and information, exchange new experience, and introduce new technologies in medical science, etc. The reported content includes the achievement reports and academic experience in basic, experimental and clinical researches, new technologies, new projects and new therapies in the diagnosis and treatment of clinical diseases, as well as the prevention and treatment experience of common, frequently-occurring and difficult diseases in the western regions and ethnic minority areas of China. The main columns of the journal include Interpretation of Guideline and Consensus, Expert Review, Special Report, Original Article, New Technology and Method, Case Report, Nursing Research, and Review.

1　Submission requirements and notes

1.1　Submissions should be novel, advanced, scientific, practical, logical and referential. The statistical data should be true, with clear viewpoints , rigorous structure , fluency in writing and accurate statistics. Original articles and review papers are required to be around 6000 words in length. All manuscripts submitted to Chinese Journal of New Clinical Medicine must include abstracts and keywords in both Chinese and English. The abstract of a case report manuscript should be around 150 words, and that of another manuscript should be around 300 to 400 words. The content of the English abstract should be consistent with that of the Chinese abstract. If necessary, the English abstract can also be longer than the Chinese one.

1.2　To submit your manuscript, please log in directly to the homepage of the journal's official website at www.zglcxyxzz.com, click on the "Author Online Submission" section, fill in the relevant content and items as required, and then submit your manuscript directly or via email at zglcxyxzz@163.com. The submitted manuscript should be punctuated accurately, and the text should be double-spaced.Pay attention to the correct writing of capital and ‌small letters in special languages‌, superscript and subscript symbols, abbreviations, etc.

1.3　Please indicate the following information under the author's name when submitting a manuscript to Chinese Journal of New Clinical Medicine: fund project (project source and number); the author's affiliation (including postal code, location, name of the institution, and department name); the author's profile (including name, educational background, degree, technical title, postgraduate supervisor if yes, major research direction, telephone number and E-mail).‌

1.4　The submitted manuscript will not be returned. Please keep a copy for yourself. According to the provisions of  Copyright Law of the People's Republic of China‌, the editorial department has the right to make textual modifications and deletions (When necessary, the editor will discuss with the author). The copyright of the manuscript belongs to the authors, but the copyright after publication belongs to Chinese Medical Doctor Association and the People's Hospital of Guangxi Zhuang Autonomous Region.

1.5　A submitted manuscript must be attached with a recommendation letter from the author's institution, clearly stating "agree to recommend, no multiple submissions, no confidentiality or authorship dispute issues". A submitted manuscript involving human biomedical research and animal experimental research (including case report) must be attached with relevant ethical approval documents. A submitted manuscript funded by a grant must be attached with the contract of the fund project (including the cover page, participant list page, and pages with the seals of the undertaking and supervising institutions). The above information should be named individually and uploaded to the Editorial Department of Chinese Journal of New Clinical Medicine as attachments.

1.6  A manuscript processing fee of 50 Chinese Yuan‌（‌CNY‌） per manuscript is required for submission (The handling fee for a manuscript must be paid before it can be submitted to the review process). The fee can be paid by mobile banking transfer or bank counter transfer.

 1.7 Complaint/appeal

If the authors have objections to the reviewers' comments, delays in manuscript processing, or doubts about publishing ethics, they can file a complaint or appeal. The authors are required to write an "appeal/complaint statement" and send it to the journal 's email address: zglcxyxzz@163.com. The complaint letters should detail the reasons for the complaint/appeal, such as providing a comprehensive and reasonable explanation of why the reviewers' comments are not agreed with. The editorial department will conduct an investigation and handle them actively.

1.8 Revision and retraction

Under normal circumstances, the papers that are officially published online or in print are regarded as the final versions. The journal generally does not correct or retract the published papers. In cases where it is truly necessary (as described below), corrections or retractions may also be made.

（1）Corrections: If there are unintentional scientific errors in the papers that do not have a significant impact on the results and conclusions of the papers, the editorial department will promptly publish correction notices in the journal, detailing the corrections made to the original text and indicating the source of the papers. When necessary, the journal may publish revised and new versions of the papers and in the new versions, and they will detail the corrections to the original papers and indicate the update date. The previous versions will also be archived and readers can access them directly, but when citing, the latest versions of the papers should be taken.

（2）Retractions: The editorial department will retract a paper and issue a retraction statement under the following circumstances: ① When the paper contains serious scientific errors, making the results and conclusions unreliable; ②for papers suspected of plagiarism, data fraud and other academic misconduct, the editorial department will launch an investigation and issue a statement to inform readers of the risks involved in the papers. The results will be made public after the investigation is completed. If it is confirmed that a paper involves academic misconduct, the editorial department will take retraction measures and issue a retraction statement.

1.9 Medical ethics

Clinical trial papers should follow the "benefit principle" and "non-harm principle" of bioethics. For papers involving biomedical research on humans and animal experiments, authors are required to provide ethical review proof documents of the research plan. If patients (subjects) are involved, informed consent forms should be signed.

All research involving clinical trials (randomized controlled trials, cohort studies, case-control studies, case reports, research conducted on humans or with specimens from humans, including psychological and social medical research based on questionnaires, in principle, authors should complete registration at a primary clinical trial registry certified by the WHO (such as ClinicalTrials.gov, the Chinese ClinicalTrial Registry, etc.) and indicate the clinical trial registration number in the manuscript.

Authors must take various preventive measures to protect the privacy of research subjects. Personal identity information such as patients' names and hospitalization ID numbers must not be involved in the manuscript. For medical research that uses identifiable human body materials or data, the consent of the subjects must be obtained in accordance with the formal procedures, and the parts that can identify the patient's identity (especially the face) must be covered in the manuscript.

1.10 The process of peer review 

The review process：the journal implements a "three-round review and three-round correction" system. After receiving a manuscript, the responsible editor will conduct an initial review. Manuscripts that lack originality, have serious scientific or technical flaws, lack valuable information, do not fall within the scope of the journal's content, or have a high rate of text repetition (The text repetition rate in the China National Knowledge Infrastructure Academic Misconduct Literature Detection System exceeds 30%) will be rejected by the editorial department within one month. Manuscripts that pass the initial review will be sent to at least one reviewer for peer review (within 1 months), using a double-blind review process (neither the author nor the reviewer knows each other's identities). After completing the external review, the manuscripts need to undergo a re-review and a final review by the chief editor (within 2 weeks). After the review is passed, the manuscript is edited by the responsible editor in accordance with the requirements of the editing norms and sent to the author for revision. The revised manuscript returned will be edited again before being sent for typesetting and proofreading, with both the editorial department and the author participating in the proofreading process. The clean proof of the manuscript must be completed, followed by the second and third proofreading, and final readthrough and proofreading before it can be selected for publication in a certain issue of the journal.

        If no handling opinion on the submitted manuscript is received within three months after receiving the reply slip from the journal, it is still under review. If the author wishes to submit to another journal, please contact our journal in advance. Special note: If the manuscript returned during the revision process does not meet the requirements of the editorial standards, it may still be rejected.